Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2013	Mar. 03, 2014	Jun. 28, 2013
Document And Entity Information
Entity Registrant Name	TherapeuticsMD, Inc.
Entity Central Index Key	0000025743
Document Type	10-K
Document Period End Date	Dec. 31, 2013
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 278,462,272
Entity Common Stock, Shares Outstanding		145,017,060
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2013

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets:
Cash	$ 54,191,260	$ 1,553,474
Accounts receivable, net of allowance for doubtful accounts of $26,555 and $42,048, respectively	1,690,753	714,425
Inventory	1,043,618	1,615,210
Other current assets	2,477,715	751,938
Total current assets	59,403,346	4,635,047
Fixed assets, net	61,318	65,673
Other Assets:
Prepaid expense	1,750,455	953,655
Intangible assets	665,588	239,555
Security deposit	135,686	31,949
Total other assets	2,551,729	1,225,159
Total assets	62,016,393	5,925,879
Current Liabilities:
Accounts payable	2,114,217	1,641,366
Deferred revenue	1,602,580	1,144,752
Other current liabilities	3,601,189	833,654
Total current liabilities	7,317,986	3,619,772
Long-Term Liabilities:
Notes payable, net of debt discount of $0 and $1,102,680, respectively		3,589,167
Accrued Interest		150,068
Total Long-term liabilities		3,739,235
Total liabilities	7,317,986	7,359,007
Commitments and Contingencies
Stockholders' Equity:
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 250,000,000 shares authorized; 144,976,757 and 99,784,982 issued and outstanding, respectively	144,977	99,785
Additional paid in capital	135,086,056	50,580,400
Accumulated deficit	(80,532,626)	(52,113,313)
Total stockholders' equity	54,698,407	(1,433,128)
Total liabilities and stockholders' equity	$ 62,016,393	$ 5,925,879

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 26,555	$ 42,048
Debt discount on notes payable	$ 0	$ 1,102,680
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	144,976,757	99,784,982
Common stock, shares outstanding	144,976,757	99,784,982

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]
Revenues, net	$ 8,775,598	$ 3,818,013	$ 2,088,177
Cost of goods sold	1,959,597	1,348,113	947,112
Gross profit	6,816,001	2,469,900	1,141,065
Operating expenses:
Sales, general, and administrative	19,014,837	14,069,701	6,406,197
Research and development	13,551,263	4,492,362	107,241
Depreciation and amortization	58,145	56,260	54,845
Total operating expense	32,624,245	18,618,323	6,568,283
Operating loss	(25,808,244)	(16,148,423)	(5,427,218)
Other income and (expense)
Miscellaneous income	34,544	3,001	6,392
Interest income	27,234
Financing costs	(1,503,922)
Interest expense	(1,165,981)	(1,905,409)	(64,380)
Loan guaranty costs	(2,944)	(45,036)	(38,159)
Loss on extinguishment of debt		(10,307,864)	(7,390,000)
Beneficial conversion feature		(6,716,504)
Total other income (expense)	(2,611,069)	(18,971,812)	(7,486,147)
Loss before taxes	(28,419,313)	(35,120,235)	(12,913,365)
Net loss	$ (28,419,313)	$ (35,120,235)	$ (12,913,365)
Net loss per share, basic and diluted	$ (0.22)	$ (0.38)	$ (0.21)
Weighted average number of shares outstanding	127,569,731	91,630,693	62,516,461

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Common Stock	Additional Paid in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2010	$ 55,487	$ 4,988,637	$ (4,079,713)	$ 964,411
Beginning balance, shares at Dec. 31, 2010	55,487,321
Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement	166	(255,919)		(255,753)
Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement, shares	165,879
Shares issued in private placement, net of cost	5,552	1,701,448		1,707,000
Shares issued in private placement, net of cost, shares	5,551,589
Shares issued in exchange for debt	21,682	8,217,455		8,239,137
Shares issued in exchange for debt, shares	21,681,958
Shares issued for exercise of options	92	17,158		17,250
Shares issued for exercise of options, shares	92,057
Options issued as compensation		183,355		183,355
Warrants issued for services		190,280		190,280
Warrants issued for loan guaranty costs-related parties		93,969		93,969
Warrants issued for financing costs		45,362		45,362
Warrants issued as financing costs-related parties		9,338		9,338
Warrants issued as compensation-related party		7,158		7,158
Net loss			(12,913,365)	(12,913,365)
Ending balance at Dec. 31, 2011	82,979	15,198,241	(16,993,078)	(1,711,858)
Ending balance, shares at Dec. 31, 2011	82,978,804
Shares issued in private placement, net of cost	3,954	7,891,531		7,895,485
Shares issued in private placement, net of cost, shares	3,953,489
Shares issued in exchange for debt	2,775	1,051,882		1,054,657
Shares issued in exchange for debt, shares	2,775,415
Shares issued for exercise of options	1,932	189,068		191,000
Shares issued for exercise of options, shares	1,931,788
Shares issued in exercise of warrants	8,145	3,093,855		3,102,000
Shares issued in exercise of warrants, shares	8,145,486
Options issued as compensation		1,832,061		1,832,061
Warrants issued for services		1,563,620		1,563,620
Warrants issued for financing costs		13,014,784		13,014,784
Warrants issued as compensation-related party		36,284		36,284
Warrants issued for cash		400		400
Cancellation of warrants issued for loan guaranty costs-related parties		(7,830)		(7,830)
Beneficial conversion feature		6,716,504		6,716,504
Net loss			(35,120,235)	(35,120,235)
Ending balance at Dec. 31, 2012	99,785	50,580,400	(52,113,313)	(1,433,128)
Ending balance, shares at Dec. 31, 2012	99,784,982			99,784,982
Shares issued in private placement, net of cost	45,117	78,605,236		78,650,353
Shares issued in private placement, net of cost, shares	45,116,352
Shares issued for exercise of options	75	30,835		30,910
Shares issued for exercise of options, shares	75,423
Warrants issued for services		867,262		867,262
Employee Share Based Compensation		3,254,083		3,254,083
Warrants issued for financing costs		1,711,956		1,711,956
Warrants issued as compensation-related party		36,284		36,284
Net loss			(28,419,313)	(28,419,313)
Ending balance at Dec. 31, 2013	$ 144,977	$ 135,086,056	$ (80,532,626)	$ 54,698,407
Ending balance, shares at Dec. 31, 2013	144,976,757			144,976,757

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Cash Flows [Abstract]
Net loss	$ (28,419,313)	$ (35,120,235)	$ (12,913,365)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement			(255,753)
Depreciation	47,883	27,484	25,686
Amortization of intangible assets	10,262	28,776	29,159
Provision for doubtful accounts	(15,493)	40,548	1,500
Loss on debt extinguishment		10,307,864	7,390,000
Beneficial conversion feature		6,716,504
Amortization of debt discount	1,102,680	1,604,240	28,719
Stock based compensation	3,207,238	1,868,345	190,513
Amortization of deferred financing costs	1,451,934		25,980
Stock based expense for services	636,917	338,457	22,630
Loan guaranty costs	2,944	45,036	38,159
Changes in operating assets and liabilities:
Accounts receivable	(1,068,619)	(728,253)	(16,409)
Inventory	571,592	(1,027,137)	29,996
Other current assets	(1,386,319)	42,281	(346,822)
Other assets	(565,706)
Accounts payable	472,851	1,334,855	188,876
Deferred revenue	457,828	1,144,752
Accrued expenses and other current liabilities	2,875,320	639,157	594,535
Other liabilities	(150,068)
Net cash flows used in operating activities	(20,768,069)	(12,737,326)	(4,966,596)
CASH FLOWS FROM INVESTING ACTIVITIES
Patent costs, net of abandoned costs	(439,034)	(206,101)	(8,870)
Payment of security deposit	(103,737)
Purchase of property and equipment	(40,790)	(66,405)	(28,766)
Net cash flows used in investing activities	(583,561)	(272,506)	(37,636)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock, net of costs	78,650,353	7,895,485	1,000,000
Proceeds bank line of credit	500,000		300,000
Proceeds from exercise of options	30,910	191,000	17,250
Proceeds from notes and loans payable		8,700,000	2,684,160
Proceeds from sale of warrants		400
Proceeds from notes and loans payable-related parties			300,000
Proceeds from sale of membership units, net of expenses			707,000
Repayment of bank line of credit	(500,000)	(300,000)
Repayment of notes payable - related party		(200,000)	(100,696)
Repayment of notes payable	(4,691,847)	(1,850,000)	(200,000)
Net cash flows provided by financing activities	73,989,416	14,436,885	4,707,714
Increase in cash	52,637,786	1,427,053	(296,518)
Cash, beginning of period	1,553,474	126,421	422,939
Cash, end of period	54,191,260	1,553,474	126,421
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	212,853	17,253	696
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:
Warrants issued for financing	1,711,956	2,509,537	148,668
Warrants issued for services	462,196	1,532,228	190,280
Warrants exercised in exchange for debt and accrued interest		3,102,000
Shares issued in exchange for debt and accrued interest		1,054,658	849,137
Notes payable issued for accrued interest		$ 15,123

THE COMPANY

12 Months Ended

Dec. 31, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

THE COMPANY

NOTE 1 – THE COMPANY

TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company organized on May 13, 2008, or VitaMed, and BocaGreenMD, Inc., a Nevada corporation incorporated on January 10, 2012, or BocaGreen. Unless the context otherwise requires, TherapeuticsMD, VitaMed, and BocaGreen collectively are sometimes referred to as “our company,” “we,” “our,” or “us.”

Nature of Business

We are a women’s healthcare product company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal dryness. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of providing equivalent efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture (through third parties) and distribute branded and generic prescription prenatal vitamins as well as over-the-counter, or OTC, vitamins and cosmetics.

Agreement and Plan of Merger with VitaMed

On July 18, 2011, we entered into an Agreement and Plan of Merger with VitaMed and our newly formed wholly owned subsidiary. In connection with the acquisition, our subsidiary merged with and into VitaMed with VitaMed surviving the merger. The merger became effective upon the filing of the Certificate of Merger with the Secretary of State of the State of Delaware on October 4, 2011. In preparation for and prior to the closing of the Merger, we completed the following required corporate actions:

	·	a reverse split of our 16,575,209 issued and outstanding shares of our common stock, par value $0.001 per share, or the Common Stock, on a ratio of 1-for-100. As a result of the reverse split, each share of Common Stock outstanding on the July 28, 2011 record date, without any action on the part of the holder thereof, became one one-hundredth of a share of Common Stock. The reverse split decreased the number of outstanding shares of our Common Stock by approximately 99%, resulting in 165,856 shares outstanding after the reverse split. The effectuation of the reverse split did not result in a change in the relative equity position or voting power of our shareholders;

	·	an increase in the number of shares of our Common Stock authorized for issuance to 250,000,000;

	·	a change in the name of our company to TherapeuticsMD, Inc.; and

	·	an amendment to our 2009 Long Term Incentive Compensation Plan to increase the number of shares of our Common Stock reserved for issuance thereunder to 25,000,000.

On the effective date of the merger, we acquired 100% of VitaMed in exchange for shares of our Common Stock.

Exchange of Securities

On the effective date of the merger, all outstanding membership units of VitaMed were exchanged for shares of our Common Stock. In addition, all outstanding options and warrants to purchase VitaMed membership units were exchanged for and converted into options and warrants to purchase shares of our Common Stock. Pursuant to the conversion ratio in the merger, we issued 58,407,331 shares of our Common Stock in exchange for the outstanding VitaMed membership units, reserved an aggregate of 10,119,796 shares of our Common Stock for issuance upon the exercise of the VitaMed options, and reserved an aggregate of 1,472,916 shares of our Common Stock for issuance upon the exercise of the warrants. After giving effect to the reverse split, and taking into consideration the 58,407,331 shares issued in exchange for the membership units, the number of shares of our Common Stock issued and outstanding as of the effective date of the merger was 58,573,187, of which the former members of VitaMed owned approximately 99%. All shares of our Common Stock issued in exchange for the VitaMed membership units and issuable upon exercise of the options and warrants were subject to a lock-up agreement for a period of 18 months from the effective date of the merger, and on a limited basis for 12 months thereafter.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances and transactions have been eliminated in consolidation.

Cash

We maintain cash at financial institutions that at times may exceed federally insured limits. We have never experienced any losses related to these funds. All of our non-interest bearing cash balances were fully insured at December 31, 2012 and 2011, resulting from the temporary federal program in effect from December 31, 2010 through December 31, 2012. Under this program, there was no limit to the amount of insurance for eligible accounts. Beginning January 1, 2013, insurance coverage reverted to $250,000 per depositor at each financial institution, at which time our non-interest bearing cash balances again exceeded federally insured limits.

Trade Accounts Receivable and Allowance for Doubtful Accounts

Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance for doubtful accounts when received. To the extent data we use to calculate these estimates does not accurately reflect bad debts; adjustments to these reserves may be required.

Inventories

Inventories represent packaged nutritional products and supplements and raw materials, which are valued at the lower of cost or market using the average-cost method. The costs of manufacturing the prescription products associated with the deferred revenue (as discussed in Revenue Recognition) are recorded as deferred costs and are included in inventory, until such time as the related deferred revenue is recognized.

Fixed Assets

Equipment

We state equipment at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expense as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years.

Leasehold Improvements

We state improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining term of the lease.

Intangible Assets

Patent and Trademarks

We have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, Intangible-Goodwill and Other, or ASC 350. Capitalized patent costs, net of accumulated amortization, include legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable. Our first patent was granted in the year ended December 31, 2013.

Impairment of Long-Lived Assets

We review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances include the following:

	·	significant declines in an asset’s market price;
	·	significant deterioration in an asset’s physical condition;
	·	significant changes in the nature or extent of an asset’s use or operation;
	·	significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;
	·	accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;
	·	current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and
	·	expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets’ fair value and respective carrying value. We determine the fair value of the assets using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods.

Fair Value of Financial Instruments

Our financial instruments consist primarily of accounts receivable, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered Level 1 assets under the fair value hierarchy. We use interest rates that are currently available to us for issuance of short- and long-term debt with similar terms and remaining maturities to estimate the fair value of our short- and long-term debt, which would be considered Level 3 inputs under the fair value hierarchy.

We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, Fair Value Measurements and Disclosures. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).

Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:

	Level 1	unadjusted quoted prices in active markets for identical assets or liabilities;

	Level 2	quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and

	Level 3	unobservable inputs for the asset or liability.

At December 31, 2013, 2012, and 2011, we had no assets or liabilities that were valued at fair value on a recurring basis.

Income Taxes

With the advent of the Merger, we determined that VitaMed would become the sole focus of our company and previous business performed by our predecessor was discontinued. Because of these events, deferred income taxes are determined by calculating the loss from operations of our company starting October 4, 2011.

We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.

In accordance with ASC 740, Income Taxes, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur. At December 31, 2013, 2012, and 2011 we had no uncertain income tax positions.

We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2013 and 2012, we had no tax positions relating to open tax returns that were considered to be uncertain.

Our tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after 2010 are subject to review.

Share-Based Compensation

In December 2004, the FASB issued ASC 718, Compensation – Stock Compensation, or ASC 718. Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective vesting periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, that requires the input of highly complex and subjective variables, including the expected life of the award and our expected stock price volatility over a period equal to or greater than the expected life of the award.

Equity instruments (“instruments”) issued to anyone other than employees are recorded on the basis of the fair value of the instruments, as required by ASC 718. ASC 505, Equity Based Payments to Non-Employees, or ASC 505, defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.

We recognize the compensation expense for all share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee’s requisite service period.

Debt Discounts

Costs incurred from parties that are providing long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the related debt using the effective interest rate method.

Revenue Recognition

We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.

Over-the-Counter Products

We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers. We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.

Prescription Products

We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and rebates.

We accept returns of unsalable product from customers within a return period of six months prior to and following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. Given the limited history of our prescription products, we currently cannot reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, we defer recognition of revenue on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription products are dispensed through patient prescriptions or expiration of the right of return.

We maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.

Shipping and Handling Costs

We expense all shipping and handling costs as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.

Advertising Costs

We expense advertising costs when incurred. Advertising costs were $11,739, $65,944 and $19,480 during the years ended December 31, 2013, December 31, 2011 and December 31, 2012, respectively.

Research and Development Expenses

Research and development, or R&D, expenses include internal R&D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal counsel. We charge internal R&D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&D activities when the activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed in future R&D activities were $2,091,809 and $189,375 for years ended December 31, 2013 and December 31, 2012, respectively. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.

Earnings Per Share

We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options and warrants. Potentially dilutive shares of our Common Stock representing 29,926,241, 25,926,987, and 13,647,788 shares of our Common Stock for 2013, 2012, and 2011, respectively, were excluded from the calculation of diluted earnings per share for these periods because their effect would have been anti-dilutive due to the net loss reported by us.

Use of Estimates

Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.

Recently Issued Accounting Pronouncements

In July, 2013, the FASB issued Accounting Standards Update, or ASU, No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force), or ASU 2013-11. The amendments in ASU 2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in ASU No. 2013-11 do not require new recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have a material impact on our consolidated financial statements.

In July 2012, the FASB issued ASU No. 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment, or ASU 2012-02. ASU 2012-02 gives entities an option to first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the long-lived intangible asset are impaired. If, based on its qualitative assessment, an entity concludes that it is more likely than not that the fair value of an indefinite lived intangible asset is less than its carrying amount, quantitative impairment testing is required. However, if an entity concludes otherwise, quantitative impairment testing is not required. ASU 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption permitted. ASU 2012-02 is not expected to have a material impact on our financial position or results of operations.

In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities, or ASU 2011-11. ASU 2011-11 enhances current disclosures about financial instruments and derivative instruments that are either offset on the statement of financial position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset on the statement of financial position. Entities are required to provide both net and gross information for these assets and liabilities in order to facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared on the basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those years. ASU 2011-11 is not expected to have a material impact on our financial position or results of operations.

We do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.

Reclassifications

Certain 2012 amounts have been reclassified to conform to current year presentation.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

INVENTORY

12 Months Ended

Dec. 31, 2013

InventoryAbstract

INVENTORY

NOTE 3 – INVENTORY

Inventory consists of the following:

	December 31,
	2013		2012
Finished product	$	621,679	$	1,124,739
Raw material		250,943		380,000
Deferred costs		170,996		110,471
TOTAL INVENTORY	$	1,043,618	$	1,615,210

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

FIXED ASSETS

12 Months Ended

Dec. 31, 2013

Property, Plant and Equipment [Abstract]

FIXED ASSETS

NOTE 5 – FIXED ASSETS

Fixed assets consist of the following:

	December 31,
	2013			2012
Equipment	$	108,458		$	67,668
Furniture and fixtures		46,625			46,625
Leasehold improvements		─			11,980
		155,083			126,273
Accumulated depreciation		(93,765	)		(60,600	)
TOTAL FIXED ASSETS	$	61,318		$	65,673

Depreciation expense for the years ended December 31, 2013, 2012, and 2011 was $45,145, $27,484 and $25,686, respectively. In December 2013, accumulated depreciation was reduced by $11,980 associated with leasehold improvements of our previously leased office property.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 7 – INTANGIBLE ASSETS

The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of December 31, 2013 and December 31, 2012:

	December 31, 2013
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:

OPERA® software patent	$	31,951	$	(499	)	$	31,452		15.8
Development costs for corporate website		91,743		(89,661	)		2,082		0.3

Non-amortizing intangible assets:

Hormone therapy drug candidate patents		572,726		—			572,726		n/a
Multiple trademarks for vitamins/supplements		59,328		—			59,328		n/a
Total	$	755,748	$	(90,160	)	$	665,588

	December 31, 2012
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:

OPERA ® software patent	$	23,722	$	0		$	23,722		0
Development costs for corporate website		91,743		(77,159	)		14,584		1.3

Non-amortizing intangible assets:

Hormone therapy drug candidate patents		180,194		—			180,194		n/a
Multiple trademarks for vitamins/supplements		21,055		—			21,055		n/a
Total	$	316,714	$	(77,159	)	$	239,555

The intangible asset related to development costs for corporate website is amortized over 36 months, which is the prescribed life for software and website development costs. The intangible asset related to OPERA® is amortized using the straight-line method over the estimated remaining useful life of 16 years, which is the life of the intellectual property patents. During the year ended December 31, 2013, there was no impairment recognized.

Amortization expense was $13,001, $28,776, $29,159 for the years ended December 31, 2013, 2012, and 2011, respectively. Estimated amortization expense for the next five years is as follows:

Year Ending December 31,	Estimated Amortization
2014	$	4,080
2015		1,997
2016		1,997
2017		1,997
2018		1,997

OTHER CURRENT LIABILITIES

12 Months Ended

Dec. 31, 2013

Other Liabilities, Current [Abstract]

OTHER CURRENT LIABILITIES

NOTE 8 – OTHER CURRENT LIABILITIES

Other current liabilities consist of the following:

	December 31,
	2013		2012
Accrued payroll and commission costs	$	941,313	$	397,210
Accrued financing costs		850,000		─
Accrued vacation		256,920		114,899
Allowance for wholesale distributor fees		306,303		107,784
Accrued legal and accounting expense		224,550		90,000
Accrued lab research		536,574		─
Accrued clinical trial costs		129,208		─
Allowance for coupons and returns		126,233		53,002
Other accrued expenses⁽¹⁾		230,088		70,759
TOTAL OTHER CURRENT LIABILITIES	$	3,601,189	$	833,654

⁽¹⁾In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at December 31, 2013 and 2012.

NOTES PAYABLE

12 Months Ended

Dec. 31, 2013

Notes Payable [Abstract]

NOTES PAYABLE

NOTE 9 – NOTES PAYABLE

Issuance and Payment of Multiple Advance Revolving Credit Note

On January 31, 2013, we entered into a business loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the Revolving Credit Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal amount, at a stated interest rate of 6% per annum. Plato was able to make advances to us from time to time under the Revolving Credit Note at our request, which advances were of a revolving nature and were able to be,made, repaid, and made from time to time. Interest payments were due and payable on the tenth day following the end of each calendar quarter in which any interest was accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the Revolving Credit Note, together with all accrued interest and other amounts payable under the Revolving Credit Note, if any, was due and payable on February 24, 2014. The Revolving Credit Note was secured by substantially all of our assets. On each of February 25 and March 13, 2013, $200,000 was drawn against the Revolving Credit Note. On March 21, 2013, we repaid $401,085, including accrued interest, and there was no balance outstanding under the Revolving Credit Note as of December 31, 2013 and February 24, 2014 when it expired. As additional consideration for the Revolving Credit Note, we granted to Plato a warrant to purchase 1,250,000 shares of our Common Stock at an exercise price $3.20 per share (see NOTE 10 for more details).

Borrowing under Business Loan Agreement and Promissory Note, as amended

In March 2011, VitaMed entered into a business loan agreement with First United Bank for a $300,000 bank line of credit for which personal guarantees and cash collateral were required. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers of our Company, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of our Company. The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012. We negotiated a one-year extension with First United to the bank line of credit, which was executed on March 19, 2012. Under the extension, borrowings bear interest at a rate of 2.35% and are due on March 1, 2013. On November 13, 2012, the outstanding balance of $299,220 was repaid in full, and we amended the line of credit to reflect a $100,000 bank line of credit. In accordance with the amended line of credit, the personal guarantee and cash collateral limited to $100,000 provided by the Reich Family Limited Partnership remained in place, while the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan. In February 2013, we borrowed $100,000 from First United Bank under the amended bank line of credit. The amended bank line of credit required a personal guarantee and cash collateral limited to $100,000, which was provided by Reich Family Limited Partnership. On April 25, 2013, we re-paid $100,735, which represented the principal and interest that was due under the amended bank line of credit. On May 1, 2013, the amended bank line of credit expired and was not renewed. Accordingly, the personal guarantee was canceled, and the cash collateral was refunded to the Reich Family Limited Partnership. During the years ended December 31, 2013, 2012, and 2011, we paid $735, $7,366, and $5,650, respectively, of interest expense, which are included in interest expense on the accompanying consolidated financial statements.

Issuance of Promissory Notes

In January and February 2012, we issued 6% promissory notes in the aggregate principal amount of $900,000, due March 1, 2012. As discussed below in Issuance and Settlement of February 2012 Notes, these promissory notes were modified on February 24, 2012 through the issuance of secured promissory notes.

Issuance and Settlement of February 2012 Notes

On February 24, 2012, we issued promissory notes, the February 2012 Notes, to an individual and an entity, or the Parties, both of which are stockholders of our company, in the principal amount of $1,358,014 and $1,357,110, respectively, and granted warrants to purchase an aggregate of 9,000,000 shares of our Common Stock pursuant to the terms of a Note Purchase Agreement, dated February 24, 2012. We received an aggregate of $1,000,000 of new funding from the Parties upon issuance of the February 2012 Notes and related warrants and surrender by the Parties of certain promissory notes, which we previously issued in the aggregate amount of $1,700,000 plus the aggregate accrued interest of $15,124 (collectively known as the “Prior Notes”). Under the February 2012 Notes, we borrowed an additional $3,000,000 from the Parties during March, April, and May 2012.

We granted 5,685,300 warrants in consideration of the modification of the Prior Notes and 3,314,700 warrants with the February Funding. We determined that the resulting modification of the Prior Notes was substantial in accordance with ASC 470-50, Modifications and Extinguishments. As such the modification was accounted for as an extinguishment and restructuring of the debt, and the 5,685,300 warrants issued in consideration of the modification were expensed (see Warrant Activity During 2012 in NOTE 10 for more details). The fair value of the Prior Notes was estimated by calculating the present value of the future cash flows discounted at a market rate of return for comparable debt instruments to be $1,517,741, resulting in a debt discount of $197,383 and recognized a loss on extinguishment of debt of $10,307,864, which represented the fair value of the 5,685,300 warrants net of the difference between the carrying amount of the Prior Notes and their fair value as of the date of the modification on the accompanying consolidated financial statements.

On June 19, 2012, we settled an aggregate amount of $3,102,000 of principal and accrued interest of the February 2012 Notes in exchange for the exercise of warrants to purchase 8,145,486 shares of our Common Stock. As discussed below in Issuance and Payment of June 2012 Notes, the remaining balance of $2,691,847 of the February 2012 Notes was modified on June 19, 2012 through the issuance of secured promissory notes, or the June 2012 Notes (see NOTE 10 for more details).

Issuance and Payment of June 2012 Notes

On June 19, 2012, we issued secured promissory notes, or the June 2012 Notes, to the Parties in the principal amounts of $2,347,128 and $2,344,719, respectively, pursuant to the terms of a Note Purchase Agreement. In connection with the June 2012 Notes, the Parties surrendered the remaining balance of the February 2012 Notes in the aggregate amount of $1,347,128 and $1,344,719, respectively, which sums included principal and accrued interest through June 19, 2012, and we received an aggregate of $2,000,000 of new funding from the Parties, or the June Funding. The principal amount of each of the June 2012 Notes, plus any additional advance made to us thereafter, together with accrued interest at the annual rate of 6%, was due in one lump sum payment on February 24, 2014. As security for our obligations under the June 2012 Notes, we entered into a Security Agreement and pledged all of our assets, tangible and intangible, as further described therein. We also granted warrants to purchase an aggregate of 7,000,000 shares of our Common Stock in connection with the June Funding. On March 21, 2013, we repaid $4,882,019, including accrued interest, leaving a balance of $21,595 in accrued interest as of March 31, 2013 on the June 2012 Notes. On April 25, 2013, the balance of accrued interest was paid in full.

Issuance and Payment of Additional Notes in 2012

In August and September 2012, we issued 6% promissory notes in the amount of $1,600,000 due on October 1, 2012, which due date was subsequently extended. These notes were paid in full in October 2012.

In September 2012, we issued a 6% promissory note for $200,000 due on October 15, 2012. This note was paid in full in October 2012.

Conversion of July 2011 Secured Notes

In July 2011, VitaMed issued two senior secured promissory notes, or the Secured Notes, each in the amount of $500,000 and also entered into a security agreement under which VitaMed pledged all of its assets to secure the obligation. The Secured Notes were assumed by us upon the merger and bore interest at the rate of 6% per annum, were due on the one year anniversary thereof, and were convertible into shares of our Common Stock at our option. We were permitted to satisfy the obligation underlying the Secured Notes by delivering such number of shares of our Common Stock calculated by dividing the then-outstanding principal balance by the Share Price. For purposes of the Secured Notes, the “Share Price” meant the lower of the most recent price at which we offered and sold shares of our Common Stock (not including any shares of our Common Stock issued upon the exercise of options and/or warrants or upon the conversion of any convertible securities) or the five-day average closing bid price immediately preceding the date of conversion. On June 19, 2012, we reached an agreement to convert the outstanding amount of the Secured Notes, representing principal and accrued interest through June 19, 2012, of $1,054,647 into an aggregate of 2,775,415 shares of our Common Stock at $0.38 per share. This resulted in a beneficial conversion feature of $6,716,504 as recorded in other income and expense on the accompanying consolidated financial statements. For the years ended December 31, 2012 and 2011, we recorded an aggregate of $33,204 and $21,453, respectively, as interest expense on the accompanying consolidated financial statements.

Issuance of VitaMed Promissory Notes

In June 2011, VitaMed issued promissory notes, or the VitaMed Notes, in the aggregate principal amount of $500,000. In connection with the VitaMed Notes, we granted warrants to purchase an aggregate of 613,718 shares of our Common Stock. The VitaMed Notes were assumed by us upon the merger and bore interest at a rate of 4% per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000, or the Funding. Upon the closing of the Funding in July 2011, as more fully described above in Conversion of July 2011 Secured Notes, two of the VitaMed Notes in the aggregate of $200,000 were paid in full. By mutual agreement, the remaining VitaMed Notes in the aggregate of $300,000 were extended. In October 2011, one of the VitaMed Notes for $50,000 was paid in full, and, by mutual agreement, certain of the VitaMed Notes in the aggregate amount of $100,000 were converted into 266,822 shares of our Common Stock at $0.38 per share, which represented the fair value of the shares of our Common Stock on the date of conversion. In June 2012, a VitaMed Note held by an unaffiliated individual was paid in full, including $2,160 in accrued interest. The remaining VitaMed Notes, held by Mr. Milligan and by BF Investment Enterprises, Ltd., which is owned by Brian Bernick, a director of our company, in the aggregate amount of $100,000, were extended to October 15, 2012. On October 4, 2012, we re-paid the outstanding VitaMed Notes in full, including $5,341 in accrued interest.

In September and October 2011, VitaMed issued convertible notes, or the VitaMed Convertible Notes, in the aggregate amount of $534,160. The VitaMed Convertible Notes bore interest at the rate of 4% per annum and were due December 1, 2011. On November 18, 2011, we entered into Debt Conversion Agreements with the holders of VitaMed Convertible Notes, pursuant to which we converted the principal and accrued interest of the VitaMed Convertible Notes into 1,415,136 shares of our Common Stock at $0.38 per share, which represented the fair value of the shares of our Common Stock on the date of conversion.

In December 2011, we issued 4% promissory notes to Mr. Finizio and Mr. Milligan for an aggregate of $100,000 due March 1, 2012. These promissory notes were subsequently extended by mutual agreement to June 1, 2012. In June 2012, we paid the promissory note held by Mr. Finizio in full, including $888 in accrued interest. Mr. Milligan’s promissory note was extended to October 15, 2012. On October 4, 2012, we paid Mr. Milligan’s promissory note in full, including $1,519 in accrued interest.

For the years ended December 31, 2012 and 2011, we recorded an aggregate of $6,344 and $2,390, respectively, as interest expense on the accompanying consolidated financial statements.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

STOCKHOLDERS' EQUITY

12 Months Ended

Dec. 31, 2013

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 10 – STOCKHOLDERS’ EQUITY

Preferred Stock

At December 31, 2013, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred stock were outstanding.

Common Stock

At December 31, 2013, we had 250,000,000 shares of Common Stock authorized for issuance, of which 144,976,757 shares of our Common Stock were issued and outstanding.

Issuances During 2013

Pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission, or the SEC, on March 14, 2013, we entered into an underwriting agreement with Jefferies LLC, or Jefferies, as the representative of the underwriters named therein, or the Jefferies Underwriters, relating to the issuance and sale of 29,411,765 shares of our Common Stock. The price to the public in the offering was $1.70 per share, and the Jefferies Underwriters agreed to purchase the shares of our Common Stock from us pursuant to the underwriting agreement at a price of $1.58 per share. The net proceeds to us from this offering was approximately $45.4 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. In addition, under the terms of the underwriting agreement, we granted the Jefferies Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of our Common Stock. The offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters exercised their option to purchase an additional 1,954,587 shares of our Common Stock to cover over-allotments. We issued these shares to the Jefferies Underwriters on April 18, 2013 and received proceeds of approximately $3.1 million, net of expenses.

On September 25, 2013, we entered into an underwriting agreement with Stifel, Nicolaus & Company, Incorporated, as the representative of the underwriters named therein, or the Stifel Underwriters, relating to the issuance and sale of 13,750,000 shares of our Common Stock. The price to the public in the offering was $2.40 per share, and the Stifel Underwriters agreed to purchase the shares of our Common Stock from us pursuant to the underwriting agreement at a price of $2.23 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.

During 2013 certain individuals exercised their right to purchase shares of our Common Stock. Options to purchase an aggregate of 75,423 shares of our Common Stock were exercised for approximately $31,000. These shares of our Common Stock were issued in part in reliance upon an exemption from the registration provisions of the Securities Act of 1933, or the Act, provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.

Issuances During 2012

During 2012, certain individuals exercised their right to purchase shares of our Common Stock. These shares were issued in reliance upon an exemption from the registration provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.

	·	Options to purchase an aggregate of 1,691,393 shares of our Common Stock were exercised for $191,000.

	·	Using the cashless exercise feature, options to purchase an aggregate of 240,395 shares of our Common Stock were exercised.

During June 2012, we settled $3,102,000 in principal and accrued interest of the February 2012 Notes in exchange for the Parties’ exercise of a portion of the related warrants for an aggregate of 8,145,486 shares of our Common Stock. The shares were issued in reliance upon an exemption from the registration provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder. During June 2012, we and the Parties also agreed to convert a portion of the February 2012 Notes, and principal and accrued interest through June 19, 2012, totaling $1,054,647, into 2,775,415 shares of our Common Stock at $0.38 per share. The shares were issued in reliance upon an exemption from the registration provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.

In September 2012, we entered into a Securities Purchase Agreement with multiple investors, relating to the issuance and sale of our Common Stock in a private placement. The private placement closed on October 2, 2012, through which we sold an aggregate of 3,953,489 shares of our Common Stock at $2.15 per share, for an aggregate purchase price of $8,500,001. In connection with the private placement, Jefferies served as our exclusive placement agent. Jefferies’ compensation for the transaction was a cash fee of $552,500. We also paid legal fees and expenses of the investors in the aggregate of $52,016, resulting in net proceeds to us from the private placement of $7,895,485. The shares were issued in reliance upon the exemptions from registration under the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder. The shares were issued directly by us and did not involve a public offering. The investors were “accredited investors” as that term is defined in Rule 501 of Regulation D and acquired our Common Stock for investment only and not with a present view toward, or for resale in connection with, the public sale or distribution thereof. Pursuant to the terms of the Securities Purchase Agreement, we agreed to file a registration statement covering the resale of these shares, which we filed on November 27, 2012.

Issuances During 2011

In December 2011, a former director of VitaMed, exercised options to purchase 92,057 shares of our Common Stock for an aggregate exercise price of $17,250.

In October and November 2011, we converted principal and accrued interest in the aggregate of $849,137 into shares of our Common Stock totaling 20,266,822 and 1,415,136, respectively (as more fully described in NOTE 9).

On October 5, 2011, we entered into a Stock Purchase Agreement with Pernix Therapeutics, LLC, a Louisiana limited liability company, or Pernix. Pursuant to the terms of the Stock Purchase Agreement, Pernix agreed to purchase 2,631,579 shares of our Common Stock at a purchase price of $0.38 per share for a total purchase price of $1,000,000. Pernix is a related party. For further details, see NOTE 12

On October 3, 2011, we effected a reverse split of our 16,575,209 issued and outstanding shares of Common Stock on a ratio of 1- for -100, resulting in 165,856 shares issued and outstanding thereafter.

Warrants

As of December 31, 2013, we had warrants outstanding to purchase an aggregate of 14,293,499 shares of our Common Stock with a weighted-average contractual remaining life of 3.9 years, and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.79 per share.

The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant.

Warrant Activity During 2013

In January 2013, we granted warrants to purchase 1,250,000 shares of our Common Stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant, (see NOTE 9). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately $1,711,956, was valued on the date of the issuance using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. At December 31, 2013, $260,022 was reported as deferred financing costs included in other current assets in the accompanying consolidated balance sheet and is being amortized over the life of the Plato Note. As of December 31, 2013, $1,451,934 was recorded as financing costs on the accompanying consolidated financial statements.

In May 2013, we entered into a consulting agreement with Sancilio & Company, Inc., or SCI, to develop drug platforms to be used in hormone replacement drug products, or the Drug Products. These services include support of our efforts to successfully obtain U.S. Federal Drug Administration, or FDA, approval for the Drug Products, including a vaginal capsule for the treatment of vulvar and vaginal atrophy. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to grant to SCI a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:

283,333 shares were earned on May 11, 2013 upon successful filing of the IND application with the FDA for the Drug Product for an estradiol-based product in a softgel vaginal capsule for the treatment of vulvar and vaginal atrophy; however, pursuant to the terms of the agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation in the accompanying consolidated financial statements;

283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. At December 31, 2013 we had $154,068 recorded as prepaid expense-short term and $308,128 recorded as prepaid expense-long term in the accompanying consolidated financial statements. During the year ended December 31, 2013, we recorded $77,034 as non-cash compensation in the accompanying consolidated financial statements; and

283,334 shares will vest upon the receipt by us of any final FDA approval of a Drug Product that SCI helped us design. It is anticipated that this event will not occur before December 2015.

Warrant Activity During 2012

In February 2012, we issued an aggregate of 5,685,300 Warrants in connection with the modification of certain existing promissory notes, or the Modification Warrants, and warrants for the purchase of an aggregate of 3,314,700 shares of our Common Stock in connection with the issuance of the February 2012 Notes, or the February 2012 Warrants (see NOTE 9). Both the Modification Warrants and the February 2012 Warrants are exercisable at $0.38 per share. The Modification Warrants have a fair value of $10,505,247, and the February 2012 Warrants have a fair value of $6,124,873. Fair value was determined on the date of the issuance using a term of five years; a volatility of 44.5%; risk free rate of 0.89%; and a dividend yield of 0%. We recorded the fair value of the Modification Warrants as part of the loss on extinguishment of debt in the accompanying consolidated financial statements. The relative fair value of the February 2012 Warrants of $859,647 was recorded as debt discount. As a result of the surrender of the February 2012 Notes on June 19, 2012, we expensed the remaining unamortized debt discount.

In March 2012, we issued an aggregate of 31,000 Warrants to five unaffiliated individuals for services rendered. These Warrants were valued on the date of the issuance using a term of five years; a volatility of 44.81%; risk free rate of 1.04%; and a dividend yield of 0%; we recorded $29,736 as consulting expense in the accompanying consolidated financial statements.

In May 2012, we issued an aggregate of 1,300,000 Warrants to an unaffiliated entity for services to be rendered over approximately five years beginning in May 2012. Services provided are to include (a) services in support of our drug development efforts, including services in support our ongoing and future drug development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and (c) other consulting services as mutually agreed upon from time to time in relation to new drug development opportunities. The Warrants were valued at $1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk free rate of 0.74%; and a dividend yield of 0%. At December 31, 2013, we had $360,528 reported as prepaid expense-short term and $593,127 recorded as prepaid expense-long term. During the year ended December 31, 2013 and the year ended December 31, 2012, we recorded $360,528 and $218,045, respectively as non-cash compensation in the accompanying consolidated financial statements. The contract will expire upon the commercial manufacture of a drug product. Based on the review, we have determined that the process will take approximately five years. As a result, we are amortizing the $1,532,228 over five years.

In June 2012, we granted aggregate of 7,000,000 Warrants in connection with the issuance of the June 2012 Notes, or the June 2012 Warrants, (see NOTE 9). Of the June 2012 Warrants issued, 6,000,000 are exercisable at $2.00 per share and 1,000,000 are exercisable at $3.00 per share. The fair value of the June 2012 Warrants of $9,424,982 was determined on the date of the issuance using a term of five years; a volatility of 44.64%; risk free rate of 0.75%; and a dividend yield of 0%. The relative fair value of the June 2012 Warrants of $1,649,890 was determined by using the relative fair value calculation method on the date of the issuance. Of the $1,649,890, $547,210 was amortized to interest expense in 2012 and as a result of the repayment of the associated debt on March 21, 2013, we amortized the remaining unamortized debt discount of $1,102,680 to interest expense.

In June 2012, we issued an aggregate of 1,500 Warrants to three unaffiliated individuals for services rendered. The Warrants were valued on the date of the issuance using a term of five years; a volatility of 44.78%; risk free rate of 0.72%; and a dividend yield of 0%. A total of $1,656 was recorded as consulting expense in the accompanying consolidated financial statements.

Warrant Activity During 2011

In December 2011, we issued 500 Warrants with a fair value of $338 to an unrelated individual for consulting services covered under a three-month agreement. The Warrants were valued on the date of the issuance using a term of 10 years; volatility of 51.83%; risk free rate of 0.91%; and a dividend yield of 0%. The Warrants vested immediately. As of December 31, 2011, of the $338 fair value, $15 was recorded as non-cash compensation and $323 was recorded as prepaid expense on the accompanying consolidated financial statements.

In October 2011, we issued 600,000 Warrants with a fair value of $133,045 to an officer of our company for services performed. The Warrants were valued on the date of the issuance using an exercise price of $0.38; a term of 10 years; volatility of 45.94%; risk free rate of 2.23%; and a dividend yield of 0%. The Warrants vest over a 44-month period beginning on November 21, 2011 (or 13,636 shares for months 1-43 and 13,652 shares for month 44). For the years ended December 31, 2013, 2012 and 2011, we recognized $36,284, $36,284 and $7,158, as non-cash compensation in the accompanying consolidated financial statements.

In December 2011, we issued 184,211 Warrants with a fair value of $25,980 to an unrelated entity for consulting services covered under a two month agreement. The Warrants were valued on the date of the issuance using an exercise price of $0.38; a term of five years; volatility of 41.04%; risk free rate of 1.08%; and a dividend yield of 0%. For the year ended December 31, 2011, the $25,980 fair value was recorded as financing expense.

In December 2011, VitaMed entered into a two-year consulting agreement with an entity providing help to evaluate improvements to existing products and new products as well as services, including research, design, compliance, scientific and regulatory affairs, and commercialization of products. As compensation, the consultant received 800,000 fully vested and non forfeitableWarrants. The Warrants were valued on the date of the issuance using an exercise price of $0.38; a term of 10 years; a volatility of 45.94%; risk free rate of 2.23%; and a dividend yield of 0%. The Warrant vested immediately. The fair value of the warrants was $177,394 at the date of grant and was amortized to research and development expense over the life of the agreement which is when the research and development activities were performed. During the years ended December 31, 2013, 2012 and 2011, we recognized $71,688, $95,582 and $10,124, respectively, in research and development expenses related to this agreement.

In July 2011, VitaMed also entered into a one-year consulting agreement with the same consultant, whereby Consultant would assist in the design, development, and distribution efforts of VitaMed’s initial product offering. As compensation, the Consultant received 200,000 fully vested non forfeitable VitaMed Warrants (or a Warrant for 245,485 shares pursuant to the Conversion Ratio). The VitaMed Warrant was valued on the date of the grant at $12,548 using an exercise price of $0.41; a term of five years; a volatility of 39.44%; risk free rate of 1.56%; and a dividend yield of 0%. The Warrant vested immediately. The fair value of the warrants was $12,548 at the date of grant and was amortized to research and development expense over the life of the agreement which is when the research and development activities were performed. During the years ended December 31, 2013, 2012 and 2011, we recognized $0, $6,936 and $5,612 respectively, in research and development expenses related to this agreement. In June 2011, VitaMed issued promissory notes, or the VitaMed Notes, in the aggregate of $500,000 with 500,000 accompanying VitaMed Warrants (or Warrants for an aggregate of 613,718 shares of our Common Stock taking into account the merger). The VitaMed Warrants were valued on the date of the issuance using an exercise price of $0.41; a term of five years; a range of volatility from 39.13% to 39.15%; risk free rate ranging from 1.38-1.65%; and a dividend yield of 0%. The Warrants vested immediately. Although the fair value was $30,993, using the appropriate accounting treatment, $28,719 was recorded as debt discount and fully amortized during 2011 with the amortized amount recorded as interest expense on the accompanying consolidated financial statements.

In March 2011, VitaMed entered into a business loan agreement with First United for a $300,000 line of credit for which personal guarantees and cash collateral were required. Personal guarantees and cash collateral limited to $100,000 each were provided by Mr. Finizio, Mr. Milligan, and Reich Family Limited LP (See NOTE 9 for more details). In consideration for the personal guarantees and cash collateral, VitaMed issued an aggregate of 499,998 VitaMed Warrants (or Warrants for an aggregate of 613,713 shares of our Common Stock taking into account the merger). The ten-year Warrants vested at the rate of an aggregate of 76,714 shares per calendar quarter end and have an exercise price of $0.24 per share. On November 13, 2012, the outstanding balance was repaid in full and business loan agreement was amended to reflect a $100,000 bank line of credit. As part of the amended line of credit, the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan. In accordance with the terms of the Warrants, Warrants previously issued to Mr. Finizio and Mr. Milligan were amended to reflect the amount vested prior to the date of the amended line of credit (179,000 each). At December 31, 2013, an aggregate of 562,571 Warrants were vested. The Warrants, with a fair value of $93,969 ($86,139 after adjusting for the effect of the amended line of credit ), were valued on the date of the issuance using a term of 10 years; a volatility of 47.89%; risk free rate of 3.48%; and a dividend yield of 0%. For the years ended December 31, 2013, 2012 and 2011, $2,944, $45,036 and $38,159, respectively was recorded as loan guaranty costs in other income and expense on the accompanying consolidated financial statements.

Summary of our Warrant activity and related information for 2011-2013

	Number of Shares Under Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance at December 31, 2010		─
Issued		3,057,627		$	0.36		7.9	$	3,483,691
Exercised		─
Expired		─
Cancelled		─
Balance at December 31, 2011		3,057,627		$	0.36		7.9	$	3,483,691
Issued		17,332,500		$	1.26		4.3	$	31,891,150
Exercised		(8,145,486	)	$	0.38
Expired		─
Cancelled		(51,142	)	$	0.24
Balance at December 31, 2012		12,193,499		$	1.63			$	17,971,994
Issued		2,100,000		$	2.72		4.8	$	5,232,500
Exercised		─
Expired		─
Cancelled		─
Balance at December 31, 2013		14,293,499		$	1.79		3.9	$	48,932,777
Vested and Exercisable at December 31, 2013		13,764,710		$	1.81		3.9	$	46,840,559

As of December 31, 2013, we had warrants outstanding with exercise prices ranging from $0.24 to $3.20 per share. As of December 31, 2013, unamortized costs associated with warrants totaled approximately $1,599,000.

The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2013, 2012 and 2011 are set forth in the table below.

	2013			2012			2011
Weighted average fair value	$	2.83		$	2.05		$	0.16
Risk-free interest rate		0.88-1.12	%		0.72-1.04	%		0.91-3.48	%
Volatility		44.29-45.89	%		44.64-44.81	%		39.13-51.83	%
Term (in years)		5-6			5			5-10
Dividend yield		0.00	%		0.00	%		0.00	%

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.

Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average of the historical volatility of the stock prices of peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2011-2013.

Options to Purchase Common Stock of the Company

In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Prior to the merger, no awards had been issued under the 2009 Plan. As of December 31, 2013 there were 13,632,742 shares of our Common Stock issued under the 2009 Plan.

On February 23, 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. There are 10,000,000 shares of our Common Stock authorized for issuance thereunder. As of December 31, 2013, there were 2,650,000 shares issued under the 2012 Plan.

The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model during the years ended December 31, 2013 are set forth in the table below.

	2013			2012			2011
Risk-free interest rate		0.65-1.71	%		0.61-2.23	%		0.91-2.54	%
Volatility		33.35-45.76	%		40.77-46.01	%		37.92-40.48	%
Term (in years)		5-6.25			5-6.25			5.5-6.25
Dividend yield		0.00	%		0.00	%		0.00	%

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual term of the option using the simplified method.

A summary of activity under the 2009 and 2012 Plans and related information for 2011-2013 follows:

	Number of Shares Under Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value

Balance at December 31, 2010		─
Granted⁽¹⁾		10,682,218		$	0.16		7.6	$	14,188,484
Exercised		(92,057	)	$	0.19
Expired		─
Cancelled		─
Balance at December 31, 2011		10,590,161		$	0.16		7.6	$	14,067,649
Granted		5,121,250		$	2.80		9.7	$	1,737,530
Exercised		(1,931,788	)	$	0.13
Expired		─
Cancelled		(46,135	)
Balance at December 31, 2012		13,733,488		$	1.16		7.7	$	26,804,117
Granted		2,583,677		$	3.31		9.8	$	4,920,981
Exercised		(75,423	)
Expired		(250	)
Cancelled		(608,750	)
Balance at December 31, 2013		15,632,742		$	1.44		7.2	$	58,878,132
Vested and Exercisable at December 31, 2013		11,282,627		$	.80		6.5	$	48,321,930

⁽¹⁾This includes (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Options including the number of shares vested.

At December 31, 2013, our outstanding options had exercise prices ranging from $0.10 to $4.67 per share.

Share-based compensation expense for options recognized in our results for the years ended December 31, 2013, 2012, and 2011 ($3,200,655, $1,832,061, and $183,355, respectively) is based on awards vested and we estimated no forfeitures. ASC 718-10 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates.

At December 31, 2013, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $3,921,000, which is expected to be recognized over a weighted-average period of 1.3 years. No tax benefit was realized due to a continued pattern of operating losses. At December 31, 2012 and 2011, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $4,391,000 and $244,000, respectively.

In December 2013, we issued a restricted stock unit, or the RSU, under our 2012 Plan to an officer for the purchase of 50,000 shares of our Common Stock. The RSU will vest on April 1, 2014 and has a fair value of $233,500. As of December 31, 2013, we recorded $53,428 of non-cash compensation.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

INCOME TAXES

12 Months Ended

Dec. 31, 2013

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 11 – INCOME TAXES

For the years ended December 31, 2013, 2012 and 2011, there was no provision for income taxes, current or deferred.

At December 31, 2013, we have a federal net operating loss carry forward of approximately $37,000,000 available to offset future taxable income through 2033.

At December 31, 2013, 2012, and 2011, we have state net operating loss carryforwards of approximately $35,000,000 available to offset future losses through 2033. We established valuation allowances equal to the full amount of the deferred tax assets because of the uncertainty of the utilization of the operating losses in future periods. We periodically assess the likelihood that we will be able to recover the deferred tax assets. We consider all available evidence, both positive and negative, including historical levels of income, expectations and risks associated with estimates of future taxable income.

Our deferred tax asset and liability as presented in the accompanying consolidated financial statements consist of the following:

	2013			2012			2011
Deferred Income Tax Assets:
Net operating losses	$	14,773,537		$	5,920,861		$	748,404
R&D Credit		547,511			186,346
Total deferred income tax asset		15,321,048			6,107,207			748,404
Valuation allowance		(15,321,048	)		(6,107,207	)		(748,404	)
Deferred Income Tax Assets, net	$	-0-		$	-0-		$	-0-

Our provision for income taxes differs from applying the statutory U.S. federal income tax rate to the income before income taxes. The primary differences result from deducting certain expenses for financial statement purposes but not for federal income tax purposes.

A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:

	2013			2012			2011
Federal statutory tax rate		35.0	%		35.0	%		35.0	%
State tax rate, net of federal tax benefit		5.8	%		5.5	%		-0-	%
Adjustment in valuation allowances		(32.4	)%		(18.2	)%		(5.8	)%
Permanent and other differences		(8.4	)%		(22.3	)%		(29.2	)%
Provision (Benefit) for Income Taxes		-0-	%		-0-	%		-0-	%

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

RELATED PARTIES

12 Months Ended

Dec. 31, 2013

RELATED PARTIES

NOTE 12 – RELATED PARTIES

Loan Guaranty

Loans from Affiliates

In June 2011, VitaMed issued promissory notes, or the VitaMed Notes, in the aggregate principal amount of $500,000, of which $100,000 was sold to affiliates. In June 2012, the affiliate notes were extended to October 15, 2012 (one held by Mr. Milligan for $50,000 and one for $50,000 held by BF Investments, LLC, which is owned by Brian Bernick, a member of the board of directors of our company. On October 4, 2012 these VitaMed Promissory Notes were paid in full including $5,341 in accrued interest.

In December 2011, we issued 4% promissory notes to Mr. Finizio and Mr. Milligan and for an aggregate of $100,000 ($50,000 each) with original due dates of March 1, 2012. These promissory notes were extended by mutual agreement to June 1, 2012. In June 2012, the VitaMed Promissory Note held by Mr. Finizio was paid in full, including $888 in accrued interest. Mr. Milligan’s VitaMed Promissory Note was extended to October 15, 2012. On October 4, 2012 this VitaMed Notes was paid in full including $1,519 in accrued interest.

Lock Up Agreements

As required by the terms of the merger agreement with VitaMed dated July 18, 2011, we entered into Lock-Up Agreements with stockholders covering the aggregate of 70,000,000 shares of our Common Stock issued pursuant to the merger or reserved for issuance pursuant to stock options and warrants. Each stockholder agreed that during a lock-up period from the date of the lock-up agreements until 18 months thereafter they would not make or cause any sale of our common stock. After the completion, each stockholder agreed not to sell or dispose of more than 2.5% of the stockholder’s aggregate Common Stock or shares reserved for issuance under stock options and warrants per quarter over the following 12-month period, or the Dribble Out Period. Upon the completion of the Dribble Out Period, the Agreements will terminate.

Purchases by Related Parties

During 2013, 2012, and 2011, we sold our products to Dr. Brian Bernick, a director of our company, in the amounts of $0, $2,632 and $20,669, respectively, while $0, $1,272 and $0 of receivables related thereto remained outstanding at December 31, 2013, 2012 and 2011, respectively.

Agreements with Pernix Therapeutics, LLC

On February 29, 2012, Cooper C. Collins, President and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of directors. We closed a stock purchase agreement with Pernix on October 5, 2011. From time to time, we have entered into agreements with Pernix in the normal course of business. All such agreements are reviewed by independent directors or a committee consisting of independent directors. During the years ended December 31, 2013, 2012, and 2011, we made purchases of approximately $0, $404,000 and $19,000, respectively, from Pernix. At December 31, 2013, 2012, and 2011, there were amounts due Pernix of approximately $46,000, $308,000 and 19,000 outstanding, respectively.

Additionally, there were amounts due to us from Pernix for legal fee reimbursement relating to a litigation matter pursuant to a license and supply agreement, in the amounts of $249,981 and $0 for the periods ending December 31, 2013 and December 31, 2012, respectively.

Warrants assigned to Related Party

In June 2012, a warrant to purchase 100,000 shares of our Common Stock was assigned to the son of the Chairman of our board of directors by a non-affiliated third party.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References+ Details

BUSINESS CONCENTRATIONS

12 Months Ended

Dec. 31, 2013

Risks and Uncertainties [Abstract]

BUSINESS CONCENTRATIONS

NOTE 13 - BUSINESS CONCENTRATIONS

We purchase our products from several suppliers with approximately 98%, 76%, and 95% of our purchases supplied from one vendor for the years ended December 31, 2013 2012, and 2011, respectively.

We sell our prescription dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated from sales to three customers, Cardinal Health, Inc., Amerisource Bergen, and McKesson Corporation accounted for 79%, 63% and 42% of our recognized revenue for years ended December 31, 2013, 2012, and 2011, respectively.

For the years ended December 31, 2013 and 2012, 64% and 28% of our recognized revenue and 97% and 98% of our deferred revenue was generated from sales to only three customers: AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation. We did not sell to these customers in prior years.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References+ Details

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 14 – COMMITMENTS AND CONTINGENCIES

Operating Lease

We lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease commencing on July 1, 2013 and expiring on September 30, 2018. The lease stipulates, among other things, average base monthly rents of $30,149 (inclusive of estimated operating expenses) and sales tax, for a total future minimum payments over the life of the lease of $1,899,414.

The straight line rental expense related to our current lease totaled $180,894 for the six months ended December 31, 2013 offset by rent income of $32,963. The rental expense related to our prior lease which expired June 30, 2013 totaled $60,168 for the six months ended June 30, 2013, and $106,315 and $122,752 for the years ended December 31, 2012 and 2011, respectively.

As of December 31, 2013, future minimum rental payments are as follows:

Years Ending December 31,
2014	$	316,039
2015		371,240
2016		382,377
2017		393,848
2018		302,748
Total minimum lease payments		1,766,252
Noncancelable sub-lease income		(38,956	)
Net minimum lease payments	$	1,727,296

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

12 Months Ended

Dec. 31, 2013

Quarterly Financial Information Disclosure [Abstract]

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

NOTE 15 – SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

Summarized quarterly financial data for fiscal years 2013 and 2012 is as follows:

	2013 Quarters
(In thousands, except per share)		1^st			2^nd			3^rd			4th
Revenues	$	1,537		$	2,081		$	2,295		$	2,863
Gross profit	$	1,157		$	1,617		$	1,646		$	2,396
Net loss	$	(6,376	)	$	(6,009	)	$	(7,673	)	$	(8,361	)

Loss per common share, basic and diluted	$	(0.06	)	$	(0.05	)	$	(0.06	)	$	(0.06	)

	2012 Quarters
(In thousands, except per share)		1^st			2^nd			3^rd			4th
Revenues	$	722		$	819		$	1,036		$	1,241
Gross profit	$	386		$	447		$	729		$	908
Net loss	$	(13,290	)	$	(11,850	)	$	(4,253	)	$	(5,727	)

Loss per common share, basic and diluted	$	(0.16	)	$	(0.14	)	$	(0.04	)	$	(0.06	)

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Principles of Consolidation

Cash

Trade Accounts Receivable and Allowance for Doubtful Accounts

Inventories

Fixed Assets

Equipment

Leasehold Improvements

We state improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining term of the lease.

Intangible Assets

Patent and Trademarks

Impairment of Long-Lived Assets

	·	significant declines in an asset’s market price;
	·	significant deterioration in an asset’s physical condition;
	·	significant changes in the nature or extent of an asset’s use or operation;
	·	significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;
	·	accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;
	·	current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and
	·	expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

Fair Value of Financial Instruments

Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:

	Level 1	unadjusted quoted prices in active markets for identical assets or liabilities;

	Level 2	quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and

	Level 3	unobservable inputs for the asset or liability.

At December 31, 2013, 2012, and 2011, we had no assets or liabilities that were valued at fair value on a recurring basis.

Income Taxes

Our tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after 2010 are subject to review.

Share-Based Compensation

Debt Discounts

Revenue Recognition

Over-the-Counter Products

Prescription Products

Shipping and Handling Costs

We expense all shipping and handling costs as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.

Advertising Costs

We expense advertising costs when incurred. Advertising costs were $11,739, $65,944 and $19,480 during the years ended December 31, 2013, December 31, 2011 and December 31, 2012, respectively.

Research and Development

Research and Development Expenses

Earnings Per Share

Use of Estimates

Recently Issued and Newly Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

Reclassifications

Certain 2012 amounts have been reclassified to conform to current year presentation.

FIXED ASSETS (Tables)

12 Months Ended

Dec. 31, 2013

Property, Plant and Equipment [Abstract]

Schedule of fixed assets

Fixed assets consist of the following:

	December 31,
	2013			2012
Equipment	$	108,458		$	67,668
Furniture and fixtures		46,625			46,625
Leasehold improvements		─			11,980
		155,083			126,273
Accumulated depreciation		(93,765	)		(60,600	)
TOTAL FIXED ASSETS	$	61,318		$	65,673

INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of December 31, 2013 and December 31, 2012:

	December 31, 2013
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:

OPERA® software patent	$	31,951	$	(499	)	$	31,452		15.8
Development costs for corporate website		91,743		(89,661	)		2,082		0.3

Non-amortizing intangible assets:

Hormone therapy drug candidate patents		572,726		—			572,726		n/a
Multiple trademarks for vitamins/supplements		59,328		—			59,328		n/a
Total	$	755,748	$	(90,160	)	$	665,588

	December 31, 2012
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:

OPERA ® software patent	$	23,722	$	0		$	23,722		0
Development costs for corporate website		91,743		(77,159	)		14,584		1.3

Non-amortizing intangible assets:

Hormone therapy drug candidate patents		180,194		—			180,194		n/a
Multiple trademarks for vitamins/supplements		21,055		—			21,055		n/a
Total	$	316,714	$	(77,159	)	$	239,555

Schedule of estimated amortization expense

Estimated amortization expense for the next five years is as follows:

Year Ending December 31,	Estimated Amortization
2014	$	4,080
2015		1,997
2016		1,997
2017		1,997
2018		1,997

OTHER CURRENT LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2013

Noncontrolling Interest [Abstract]

Schedule of other current liabilities

Other current liabilities consist of the following:

	December 31,
	2013		2012
Accrued payroll and commission costs	$	941,313	$	397,210
Accrued financing costs		850,000		─
Accrued vacation		256,920		114,899
Allowance for wholesale distributor fees		306,303		107,784
Accrued legal and accounting expense		224,550		90,000
Accrued lab research		536,574		─
Accrued clinical trial costs		129,208		─
Allowance for coupons and returns		126,233		53,002
Other accrued expenses⁽¹⁾		230,088		70,759
TOTAL OTHER CURRENT LIABILITIES	$	3,601,189	$	833,654

STOCKHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2013

Equity [Abstract]

Schedule of warrant activity

Summary of our Warrant activity and related information for 2011-2013

	Number of Shares Under Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance at December 31, 2010		─
Issued		3,057,627		$	0.36		7.9	$	3,483,691
Exercised		─
Expired		─
Cancelled		─
Balance at December 31, 2011		3,057,627		$	0.36		7.9	$	3,483,691
Issued		17,332,500		$	1.26		4.3	$	31,891,150
Exercised		(8,145,486	)	$	0.38
Expired		─
Cancelled		(51,142	)	$	0.24
Balance at December 31, 2012		12,193,499		$	1.63			$	17,971,994
Issued		2,100,000		$	2.72		4.8	$	5,232,500
Exercised		─
Expired		─
Cancelled		─
Balance at December 31, 2013		14,293,499		$	1.79		3.9	$	48,932,777
Vested and Exercisable at December 31, 2013		13,764,710		$	1.81		3.9	$	46,840,559

Schedule of weighted average fair value per share and assumptions used in the Black-Scholes Model of warants

	2013			2012			2011
Weighted average fair value	$	2.83		$	2.05		$	0.16
Risk-free interest rate		0.88-1.12	%		0.72-1.04	%		0.91-3.48	%
Volatility		44.29-45.89	%		44.64-44.81	%		39.13-51.83	%
Term (in years)		5-6			5			5-10
Dividend yield		0.00	%		0.00	%		0.00	%

Schedule of assumptions used in the Black-Scholes Model of stock options

The assumptions used in the Black-Scholes Model during the years ended December 31, 2013 are set forth in the table below.

	2013			2012			2011
Risk-free interest rate		0.65-1.71	%		0.61-2.23	%		0.91-2.54	%
Volatility		33.35-45.76	%		40.77-46.01	%		37.92-40.48	%
Term (in years)		5-6.25			5-6.25			5.5-6.25
Dividend yield		0.00	%		0.00	%		0.00	%

Schedule of Option activity

A summary of activity under the 2009 and 2012 Plans and related information for 2011-2013 follows:

	Number of Shares Under Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value

Balance at December 31, 2010		─
Granted⁽¹⁾		10,682,218		$	0.16		7.6	$	14,188,484
Exercised		(92,057	)	$	0.19
Expired		─
Cancelled		─
Balance at December 31, 2011		10,590,161		$	0.16		7.6	$	14,067,649
Granted		5,121,250		$	2.80		9.7	$	1,737,530
Exercised		(1,931,788	)	$	0.13
Expired		─
Cancelled		(46,135	)
Balance at December 31, 2012		13,733,488		$	1.16		7.7	$	26,804,117
Granted		2,583,677		$	3.31		9.8	$	4,920,981
Exercised		(75,423	)
Expired		(250	)
Cancelled		(608,750	)
Balance at December 31, 2013		15,632,742		$	1.44		7.2	$	58,878,132
Vested and Exercisable at December 31, 2013		11,282,627		$	.80		6.5	$	48,321,930

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References+ Details

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2013

Income Tax Disclosure [Abstract]

Schedule of deferred tax assets and liabilities

Our deferred tax asset and liability as presented in the accompanying consolidated financial statements consist of the following:

	2013			2012			2011
Deferred Income Tax Assets:
Net operating losses	$	14,773,537		$	5,920,861		$	748,404
R&D Credit		547,511			186,346
Total deferred income tax asset		15,321,048			6,107,207			748,404
Valuation allowance		(15,321,048	)		(6,107,207	)		(748,404	)
Deferred Income Tax Assets, net	$	-0-		$	-0-		$	-0-

Schedule of tax rate reconciliation

A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:

	2013			2012			2011
Federal statutory tax rate		35.0	%		35.0	%		35.0	%
State tax rate, net of federal tax benefit		5.8	%		5.5	%		-0-	%
Adjustment in valuation allowances		(32.4	)%		(18.2	)%		(5.8	)%
Permanent and other differences		(8.4	)%		(22.3	)%		(29.2	)%
Provision (Benefit) for Income Taxes		-0-	%		-0-	%		-0-	%

SELECTED QUARTERLY FINANCIAL DATA (Tables)

12 Months Ended

Dec. 31, 2013

Quarterly Financial Information Disclosure [Abstract]

Schedule of quarterly unaudited summary information

Summarized quarterly financial data for fiscal years 2013 and 2012 is as follows:

	2013 Quarters
(In thousands, except per share)		1^st			2^nd			3^rd			4th
Revenues	$	1,537		$	2,081		$	2,295		$	2,863
Gross profit	$	1,157		$	1,617		$	1,646		$	2,396
Net loss	$	(6,376	)	$	(6,009	)	$	(7,673	)	$	(8,361	)

Loss per common share, basic and diluted	$	(0.06	)	$	(0.05	)	$	(0.06	)	$	(0.06	)

	2012 Quarters
(In thousands, except per share)		1^st			2^nd			3^rd			4th
Revenues	$	722		$	819		$	1,036		$	1,241
Gross profit	$	386		$	447		$	729		$	908
Net loss	$	(13,290	)	$	(11,850	)	$	(4,253	)	$	(5,727	)

Loss per common share, basic and diluted	$	(0.16	)	$	(0.14	)	$	(0.04	)	$	(0.06	)

THE COMPANY (Details Narrative)	0 Months Ended				0 Months Ended
THE COMPANY (Details Narrative)	Jul. 28, 2011	Dec. 31, 2013	Dec. 31, 2012	Jul. 29, 2011	Oct. 04, 2011 Agreement and Plan of Merger with VitaMed	Jul. 29, 2011 Agreement and Plan of Merger with VitaMed	Jul. 28, 2011 Agreement and Plan of Merger with VitaMed	Oct. 04, 2011 Agreement and Plan of Merger with VitaMed Options	Oct. 04, 2011 Agreement and Plan of Merger with VitaMed Warrants
Common stock, shares issued	16,575,209	144,976,757	99,784,982	165,856		165,856	16,575,209
Common stock, shares outstanding	16,575,209	144,976,757	99,784,982	165,856		165,856	16,575,209
Reverse stock split ratio	1 for 100					1 for 100
Percentage decrease in holding due to merger						99.00%
Common stock, shares authorized		250,000,000	250,000,000		250,000,000
Percentage of holding acquired					100.00%
Shares issued in exchange for outstanding membership units					58,407,331
Shares reserved for future isssuance					70,000,000			10,119,796	1,472,916
Description of lock in period					Each stockholder agreed that during a lock-up period from the date of the lock-up agreements until 18 months thereafter they would not make or cause any sale of our common stock. After the completion, each stockholder agreed not to sell or dispose of more than 2.5% of the stockholder's aggregate Common Stock or shares reserved for issuance under stock options and warrants per quarter over the following 12-month period, or the Dribble Out Period. Upon the completion of the Dribble Out Period, the Agreements will terminate.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]
Advertising Costs	$ 11,739	$ 19,480	$ 65,944
Advance payments for future research and development activities	$ 2,091,809	$ 189,375
Anti-dilutive shares excluded from earnings per share calculation	29,926,241	25,926,987	13,647,788
Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

INVENTORY (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventory
Finished Product	$ 621,679	$ 1,124,739
Raw Material	250,943	380,000
Deferred Costs	170,996	110,471
Inventory	$ 1,043,618	$ 1,615,210

OTHER CURRENT ASSETS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Other Current Assets
Prepaid R&D costs	$ 1,267,588	$ 189,375
Prepaid consulting	530,596	432,216
Deferred financing costs	260,022
Other receivables-related party	249,981
Prepaid other	169,528	127,403
Prepaid guaranty costs		2,944
TOTAL OTHER CURRENT ASSETS	$ 2,477,715	$ 751,938

- Definition

The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).

+ References+ Details

FIXED ASSETS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fixed assets, gross	$ 155,083	$ 126,273
Accumulated depreciation	(93,765)	(60,600)
Fixed Assets, net	61,318	65,673
Equipment
Fixed assets, gross	108,458	67,668
Furniture and Fixtures
Fixed assets, gross	46,625	46,625
Leasehold Improvements
Fixed assets, gross		$ 11,980

PREPAID EXPENSE (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Other Assets
Prepaid R&D costs	$ 824,221	$ 953,655
Prepaid manufacturing costs	899,000
Accreted prepaid costs	27,234
TOTAL PREPAID EXPENSE	$ 1,750,455	$ 953,655

INTANGIBLE ASSETS (Details Narrative) (USD $)	12 Months Ended
INTANGIBLE ASSETS (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 10,262	$ 28,776	$ 29,159

INTANGIBLE ASSETS (Details ) (USD $)	12 Months Ended
INTANGIBLE ASSETS (Details ) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets
Accumulated Amortization	$ (90,160)	$ (77,159)
Indefinite-Lived Intangible Assets
Gross Carrying Amount	755,748	316,714
Net Amount	665,588	239,555
Gross Carrying Amount	755,748	316,714
Net Amount	665,588	239,555
Hormone therapy drug candidate patents
Indefinite-Lived Intangible Assets
Gross Carrying Amount	572,726	180,194
Net Amount	572,726	180,194
Multiple trademarks for vitamins/supplements
Indefinite-Lived Intangible Assets
Gross Carrying Amount	59,328	21,055
Net Amount	59,328	21,055
OPERA® software patent
Finite-Lived Intangible Assets
Gross Carrying Amount	31,951	23,722
Accumulated Amortization	(499)	0
Net Amount	31,452	23,722
Weighted Average Amortization Period	15 years 9 months 18 days	0 years
Development costs for corporate website
Finite-Lived Intangible Assets
Gross Carrying Amount	91,743	91,743
Accumulated Amortization	(89,661)	(77,159)
Net Amount	$ 2,082	$ 14,584
Weighted Average Amortization Period	0 years 3 months 18 days	1 year 3 months 18 days

INTANGIBLE ASSETS (Details 1) (USD $)	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
2014	$ 4,080
2015	1,997
2016	1,997
2017	1,997
2018	$ 1,997

OTHER CURRENT LIABILITIES (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Other Liabilities, Current [Abstract]

Accrued payroll and commission costs

$ 941,313

$ 397,210

Accrued financing costs

850,000

Accrued vacation

256,920

114,899

Allowance for wholesale distributor fees

306,303

107,784

Accrued legal and accounting expense

224,550

90,000

Accrued lab research

536,574

Accrued clinical trial costs

129,208

Allowance for coupons and returns

126,233

53,002

Other accrued expenses

230,088

^[1]

70,759

^[1]

TOTAL OTHER CURRENT LIABILITIES

$ 3,601,189

$ 833,654

[1]	In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at December 31, 2013 and 2012.

NOTES PAYABLE (Details Narrative) (USD $)	12 Months Ended				0 Months Ended		0 Months Ended					0 Months Ended		1 Months Ended					12 Months Ended						0 Months Ended			0 Months Ended	3 Months Ended		0 Months Ended	1 Months Ended			0 Months Ended			0 Months Ended
NOTES PAYABLE (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Nov. 13, 2012 Mr. Finizio	Nov. 13, 2012 Mr. Milligan	Nov. 13, 2012 Reich Family Limited LP	Mar. 21, 2013 Multiple Advance Revolving Credit Note (Plato Warrant)	Mar. 13, 2013 Multiple Advance Revolving Credit Note (Plato Warrant)	Feb. 25, 2013 Multiple Advance Revolving Credit Note (Plato Warrant)	Jan. 31, 2013 Multiple Advance Revolving Credit Note (Plato Warrant)	Dec. 31, 2013 Multiple Advance Revolving Credit Note (Plato Warrant)	Apr. 25, 2013 VitaMed Promissory Notes	Mar. 19, 2012 VitaMed Promissory Notes	Feb. 28, 2013 VitaMed Promissory Notes	Jun. 30, 2012 VitaMed Promissory Notes	Oct. 30, 2011 VitaMed Promissory Notes	Jun. 30, 2011 VitaMed Promissory Notes	Mar. 31, 2011 VitaMed Promissory Notes	Dec. 31, 2013 VitaMed Promissory Notes	Dec. 31, 2012 VitaMed Promissory Notes	Dec. 31, 2011 VitaMed Promissory Notes	Nov. 13, 2012 VitaMed Promissory Notes	Mar. 31, 2011 VitaMed Promissory Notes Mr. Finizio	Mar. 31, 2011 VitaMed Promissory Notes Mr. Milligan	Nov. 13, 2012 VitaMed Promissory Notes Reich Family Limited LP	Mar. 31, 2011 VitaMed Promissory Notes Reich Family Limited LP	Feb. 29, 2012 Issuance of 6% Promissory Notes (January and February 2012)	Feb. 24, 2012 February 2012 Notes Issued To Individual And Entity	May 31, 2012 February 2012 Notes Issued To Individual And Entity	Jun. 19, 2012 February 2012 Notes Issued To Individual And Entity	Jun. 19, 2012 February 2012 Notes/ Warrants	Jun. 30, 2013 February 2012 Notes/ Warrants	Feb. 29, 2012 February 2012 Notes/ Warrants	Feb. 24, 2012 February 2012 Notes/ Warrants	Feb. 24, 2012 February 2012 Notes Issued To Parties	Jun. 19, 2012 February 2012 Notes Issued To Parties	Jun. 19, 2012 June 2012 Notes Issued To Individual And Entity	Jun. 19, 2012 June 2012 Notes Issued To Parties	Apr. 25, 2013 June 2012 Notes (secured promissory notes)	Mar. 21, 2013 June 2012 Notes (secured promissory notes)	Jun. 19, 2012 June 2012 Notes (secured promissory notes)
Debt Instrument [Line Items]
Maximum principal amount										$ 10,000,000
Stated interest rate										6.00%			2.35%					3.02%
Description of interest payment										Interest payments were due and payable on the tenth day following the end of each calendar quarter			Under the extension, borrowings bear interest at a rate of 2.35% and are due on March 1, 2013.					The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012
Proceeds from revolving credit note								200,000	200,000
Repayment of revolving credit note							401,085
Revolving credit outstanding											0
Number of shares purchased										1,250,000							613,718																5,685,300	3,314,700	5,685,300						9,000,000
Exercise price of warrants (in dollars per unit)										3.20							0.41																0.38
Line of credit				179,000	179,000	179,000												300,000				299,220	100,000	100,000		100,000
Repayments of lines of credit	500,000	300,000										100,735													299,220
Proceeds from lines of credit	500,000		300,000											100,000											100,000
Line of credit facility decrease forgiveness					100,000
Interest expense	1,165,981	1,905,409	64,380																735	7,366	5,650
Aggregate principal amount																	500,000										900,000	1,358,014							1,357,110		2,347,128	2,344,719
Proceeds from notes payable																												1,000,000	3,000,000						1,700,000			2,000,000
Repayments of notes payable	4,691,847	1,850,000	200,000													50,000	200,000																		1,700,000					4,882,019
Acrued interest		150,068																																	15,124					21,595
Fair value of notes																																			1,517,741
Debt discount																																	859,647		197,383
Recognized loss on extinguishment of debt		(10,307,864)	(7,390,000)																																10,307,864
Aggregate principal and accrued interest																															3,102,000
Amount of shares issued in exercise of warrants																															8,145,486	8,145,486
Remaining balance of notes																														1,347,128	2,691,847					1,344,719
Interest rate																	4.00%																								6.00%
Description of interest rate terms																	The VitaMed Notes were assumed by us upon the merger and bore interest at a rate of 4% per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000, or the Funding.																								Accrued interest at the annual rate of 6%, was due in one lump sum payment on February 24, 2014.
Acrued interest paid	$ 212,853	$ 17,253	$ 696												$ 2,160																								$ 21,595

NOTES PAYABLE (Details Narrative 1) (USD $)	12 Months Ended			1 Months Ended		1 Months Ended		0 Months Ended	12 Months Ended					1 Months Ended					2 Months Ended	12 Months Ended			0 Months Ended		1 Months Ended	12 Months Ended		1 Months Ended	0 Months Ended
NOTES PAYABLE (Details Narrative 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 31, 2012 6% Notes issued in August and September 2012	Sep. 30, 2012 6% Notes issued in August and September 2012	Oct. 31, 2012 6% Notes issued in September 2012	Sep. 30, 2012 6% Notes issued in September 2012	Jun. 19, 2012 VitaMed July 2011 Secured Notes Number	Dec. 31, 2012 VitaMed July 2011 Secured Notes	Dec. 31, 2011 VitaMed July 2011 Secured Notes	Jul. 31, 2011 VitaMed July 2011 Secured Notes	Jul. 31, 2011 VitaMed July 2011 First Secured Notes	Jul. 31, 2011 VitaMed July 2011 Second Secured Notes	Jun. 30, 2012 VitaMed Promissory Notes	Nov. 30, 2011 VitaMed Promissory Notes	Oct. 30, 2011 VitaMed Promissory Notes Number	Oct. 31, 2011 VitaMed Promissory Notes	Jun. 30, 2011 VitaMed Promissory Notes	Nov. 30, 2011 VitaMed Promissory Notes	Dec. 31, 2013 VitaMed Promissory Notes	Dec. 31, 2012 VitaMed Promissory Notes	Dec. 31, 2011 VitaMed Promissory Notes	Oct. 04, 2012 VitaMed Promissory Notes Brian Bernick	Jun. 30, 2012 VitaMed Promissory Notes Brian Bernick	Oct. 31, 2011 VitaMed Convertible Notes Number	Dec. 31, 2012 Notes Issued to Mr. Finizio And Mr. Milligan	Dec. 31, 2011 Notes Issued to Mr. Finizio And Mr. Milligan	Jun. 30, 2012 Notes Issued to Mr. Finizio	Oct. 04, 2012 Notes Issued to Mr. Milligan
Debt Instrument [Line Items]
Aggregate principal amount					$ 1,600,000		$ 200,000					$ 500,000	$ 500,000					$ 500,000							$ 534,160		$ 100,000
Repayments of notes payable	4,691,847	1,850,000	200,000	1,600,000		200,000										50,000		200,000					100,000
Interest rate											6.00%							4.00%							4.00%
Aggregate principal and accrued interest								1,054,647
Numbers of shares converted for debt								2,775,415							1,415,136	266,822	20,266,822								1,415,136
Conversion price (in dollars per share)								$ 0.38								$ 0.38									$ 0.38
Value of debt converted to shares		(6,716,504)						6,716,504								100,000			849,137
Interest expense	1,165,981	1,905,409	64,380						33,204	21,453										735	7,366	5,650				6,344	2,390
Numbers of shares purchased																		613,718
Description of interest rate terms																		The VitaMed Notes were assumed by us upon the merger and bore interest at a rate of 4% per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000, or the Funding.
Acrued interest paid	212,853	17,253	696											2,160									5,341					888	1,519
Aggregate remaining principal amount																								$ 100,000

STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	0 Months Ended	12 Months Ended				0 Months Ended	1 Months Ended	0 Months Ended	1 Months Ended					2 Months Ended	0 Months Ended		12 Months Ended	0 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	Jul. 28, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 29, 2011	Oct. 05, 2011 Stock Purchase Agreement With Pernix Therapeutics LLC	Sep. 30, 2013 Private placement	Jun. 19, 2012 February 2012 Notes/ Warrants	Jun. 30, 2013 February 2012 Notes/ Warrants	Dec. 31, 2011 VitaMed Promissory Notes	Nov. 30, 2011 VitaMed Promissory Notes	Oct. 30, 2011 VitaMed Promissory Notes Number	Oct. 31, 2011 VitaMed Promissory Notes	Nov. 30, 2011 VitaMed Promissory Notes	Apr. 20, 2013 Jefferies LLC (Underwriters)	Mar. 20, 2013 Jefferies LLC (Underwriters)	Dec. 31, 2013 Jefferies LLC (Underwriters)	Sep. 25, 2013 Stifel, Nicolaus & Company (Underwriters)
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred stock, par value (in dollars per share)		$ 0.001	$ 0.001
Preferred stock, shares issued		0	0
Preferred stock, shares outstanding		0	0
Common stock, shares authorized		250,000,000	250,000,000
Common stock, shares issued	16,575,209	144,976,757	99,784,982		165,856
Common stock, shares outstanding	16,575,209	144,976,757	99,784,982		165,856
Number of shares issued during the period						2,631,579	3,953,489										29,411,765	13,750,000
Share price (in dollars per share)							$ 2.15										$ 1.70	$ 2.40
Share price to underwritters (in dollars per share)						$ 0.38											$ 1.58	$ 2.23
Number of shares issued during the period,value		$ 78,650,353	$ 7,895,485	$ 1,707,000		$ 1,000,000	$ 7,895,485										$ 45,400,000	$ 30,200,000
Additional period for purchase share																	30 days
Total Additional common stock issued under shelf registration statement																4,411,765
Additional common stock issued under shelf registration statement															1,954,587
Additional common stock issued under shelf registration statement,value															3,100,000
Numbers of options to purchase shares of common stock exercised for cash			1,691,393
Options to purchase shares of common stock, value		30,910	191,000	17,250						17,250
Numbers of options to purchase shares of common stock, cashless exercise			240,395
Number of shares issued in exercise of warrants			3,102,000						3,102,000
Amount of shares issued in exercise of warrants								8,145,486	8,145,486
Value of debt converted to shares			(6,716,504)						1,054,647			100,000		849,137
Numbers of shares converted for debt									2,775,415		1,415,136	266,822	20,266,822
Conversion price (in dollars per share)									$ 0.38			$ 0.38
Transaction cash fees							552,500
Legal fees and expenses paid							52,016
Aggregate purchase price of common stock sold							$ 8,500,001
Reverse stock split ratio	1 for 100

STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)	12 Months Ended						1 Months Ended	0 Months Ended			12 Months Ended		1 Months Ended			12 Months Ended		0 Months Ended	12 Months Ended			1 Months Ended		12 Months Ended	1 Months Ended	12 Months Ended			1 Months Ended	12 Months Ended	1 Months Ended		12 Months Ended				1 Months Ended	12 Months Ended	1 Months Ended		1 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Nov. 13, 2012 Mr. Finizio	Nov. 13, 2012 Mr. Milligan	Nov. 13, 2012 Reich Family Limited LP	May 31, 2013 Sancilio & Company Warrants	Jun. 30, 2013 Sancilio & Company Warrants 1st Installments	May 11, 2013 Sancilio & Company Warrants 1st Installments	Jun. 30, 2013 Sancilio & Company Warrants 2nd Installments	Dec. 31, 2013 Sancilio & Company Warrants 2nd Installments	Dec. 31, 2013 Sancilio & Company Warrants 3rd Installments	Feb. 29, 2012 Modification Warrants	Mar. 31, 2012 Warrants Issued to Unaffiliated Individuals Number	May 31, 2012 Warrants Issued to Unaffiliated Entity	Dec. 31, 2013 Warrants Issued to Unaffiliated Entity	Dec. 31, 2012 Warrants Issued to Unaffiliated Entity	Jun. 19, 2012 June 2012 Notes/Warrants	Dec. 31, 2012 June 2012 Notes/Warrants	Jun. 19, 2012 June 2012 Notes/Warrants 1st Issue	Jun. 19, 2012 June 2012 Notes/Warrants 2nd Issue	Jun. 30, 2012 Warrants Issued to Unaffiliated Individuals Number	Dec. 31, 2011 Warrants Issued to Unrelated Individual for Consulting Services	Dec. 31, 2011 Warrants Issued to Unrelated Individual for Consulting Services	Oct. 31, 2011 Warrants Issued Officers	Dec. 31, 2013 Warrants Issued Officers	Dec. 31, 2012 Warrants Issued Officers	Dec. 31, 2011 Warrants Issued Officers	Dec. 31, 2011 Warrants Issued to Unrelated Entity for Consulting Services	Dec. 31, 2011 Warrants Issued to Unrelated Entity for Consulting Services	Dec. 31, 2011 Vested non forfeitable VitaMed Warrants	Mar. 31, 2011 Vested non forfeitable VitaMed Warrants	Dec. 31, 2013 Vested non forfeitable VitaMed Warrants Number	Dec. 31, 2012 Vested non forfeitable VitaMed Warrants	Dec. 31, 2011 Vested non forfeitable VitaMed Warrants	Nov. 13, 2012 Vested non forfeitable VitaMed Warrants	Jan. 31, 2013 Multiple Advance Revolving Credit Note (Plato Warrant)	Dec. 31, 2013 Multiple Advance Revolving Credit Note (Plato Warrant)	Feb. 29, 2012 February 2012 Notes/ Warrants	Feb. 24, 2012 February 2012 Notes/ Warrants	Jun. 30, 2011 VitaMed Promissory Notes	Nov. 13, 2012 VitaMed Promissory Notes	Mar. 31, 2011 VitaMed Promissory Notes	Mar. 31, 2011 VitaMed Promissory Notes Mr. Finizio	Mar. 31, 2011 VitaMed Promissory Notes Mr. Milligan	Mar. 31, 2011 VitaMed Promissory Notes Reich Family Limited LP	Dec. 31, 2013 Minimum	Dec. 31, 2013 Maximum	Dec. 31, 2013 Weighted Average
Warrants:
Warrants outstanding	$ 14,293,499
Weighted-average contractual remaining life	3 years 10 months 24 days
Exercise price of warrants (in dollars per share)							2.01						0.38		2.57					2.00	3.00				0.38				0.38	0.38	0.41	0.24			0.41		3.20		0.38		0.41						0.24	3.20	1.79
Unamortized costs of warrants	1,599,000
Number of shares purchased							850,000		283,333	283,333		283,334	3,314,700	31,000	1,300,000			7,000,000		6,000,000	1,000,000	1,500	500	500	600,000	7,158	36,284	36,284	184,211	184,211	200,000		93,969		200,000		1,250,000		5,685,300	3,314,700	613,718
Expiration date of warrants																																					Jan. 31, 2019
Vesting date of warrants									Jun. 30, 2013																												Oct. 31, 2013
Fair value of warrants								405,066		462,196			6,124,873		1,532,228			9,424,982					338	338	133,045				25,980	25,980	12,548				12,548		1,711,956		10,505,247		30,993
Expected term								5 years		5 years			5 years	5 years	5 years			5 years				5 years	10 years		10 years				5 years		5 years		10 years				6 years		5 years		5 years
Volatility rate								45.89%		45.84%			44.50%	44.81%	44.71%			44.64%				44.78%	51.83%		45.94%				41.04%		39.44%		47.89%				44.29%		44.50%
Risk free rate								45.89%		1.41%			89.00%	1.04%	0.74%			0.75%				0.72%	0.91%		2.23%				1.08%		1.56%		3.48%				0.88%		89.00%
Dividend yield								0.00%		0.00%			0.00%	0.00%	0.00%			0.00%				0.00%	0.00%		0.00%				0.00%		0.00%		0.00%				0.00%		0.00%		0.00%
Amortization deferred financing costs																1,532,228			547,210																			260,022			28,719
Deferred financing costs	260,022																																					1,451,934
Number of shares purchased forfeit							833,000
Valuation method of warrants								Black-Scholes Model
Non-cash compensation recongised								405,066			77,034					360,528	218,045							15		7,158	36,284	36,284
Prepaid expense-short term											154,068				360,528	360,528
Prepaid expense-long term											308,128				593,127	593,127
Prepaid expense																							323	323
Fair value of warrants by relative fair value calculation method																		1,649,890
Remaining amortization deferred financing costs																			1,102,680
Debt discount																																							859,647
Number of unaffiliated individuals														5								3
Professional fees														29,736								1,656
Description of vesting period of warrants																									The Warrants vest over a 44-month period beginning on November 21, 2011 (or 13,636 shares for months 1-43 and 13,652 shares for month 44).							Warrants vested at the rate of an aggregate of 76,714 shares per calendar quarter end.
Agreement covering period																							3 months
Financing expense																														25,980
Amortization research and development expense																															12,548
Research and development expense	13,551,263	4,492,362	107,241																														0	6,936	5,612
Note payable																																									500,000
Minimum volatility rate																																									39.13%
Maximum volatility rate																																									39.15%
Minimum risk free rate																																									1.38%
Maximum risk free rate																																									1.65%
Line of credit				179,000	179,000	179,000																										300,000				100,000						299,220	300,000	100,000	100,000	100,000
Warrants issued																																613,713
Number of warrants vested																																	562,571
Loan guaranty costs	$ 2,944	$ 45,036	$ 38,159																														$ 2,944	$ 45,036	$ 38,159

STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)	12 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Numbers of options oustanding
Share-based compensation expense	$ 3,207,238	$ 1,868,345	$ 190,513
Total unrecognized estimated compensation expense	3,921,000	4,391,000	244,000
Recognized weighted-average period	1 year 3 months 18 days
Minimum
Option exercise prices (in dollars per shares)	$ 0.10
Maximum
Option exercise prices (in dollars per shares)	$ 4.67
2009 Long Term Incentive Compensation Plan
Description of plan	To provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards.
Number of shares authorized for issuance	25,000,000
Number of shares issued	13,632,742
Non Qualified 2012 Stock Incentive Plan
Description of plan	Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.
Number of shares authorized for issuance	10,000,000
Number of shares issued	2,650,000
Non Qualified 2012 Stock Incentive Plan \| Restricted stock unit
Share-based compensation expense	53,428
Number of shares purchased	50,000
Vesting date	2014-04-01
Fair value	$ 233,500

STOCKHOLDERS' EQUITY (Details) (Warrants, USD $)	12 Months Ended
STOCKHOLDERS' EQUITY (Details) (Warrants, USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Warrants
Number of shares under warrant
Warrants outstanding, beginning	12,193,499	3,057,627
Warrants issued	2,100,000	17,332,500	3,057,627
Warrants exercised		(8,145,486)
Warrants expired
Warrants cancelled		(51,142)
Warrants outstanding, ending	14,293,499	12,193,499	3,057,627
Vested and Exercisable	13,764,710
Weighted Average Exercise Price
Warrants outstanding, beginning	1.63	0.36
Warrants issued	2.72	1.26	0.36
Warrants exercised		0.38
Warrants cancelled		0.24
Warrants outstanding, ending	1.79	1.63	0.36
Vested and Exercisable	1.81
Weighted Average Remaining Contractual Life
Warrants outstanding, beginning		7 years 10 months 24 days
Warrants issued	4 years 9 months 18 days	4 years 3 months 18 days	7 years 10 months 24 days
Warrants outstanding, ending	3 years 10 months 24 days		7 years 10 months 24 days
Vested and Exercisable	3 years 10 months 24 days
Aggregate Intrinsic Value
Warrants outstanding, beginning	$ 17,971,994	$ 3,483,691
Warrants issued	5,232,500	31,891,150	3,483,691
Warrants outstanding, ending	48,932,777	17,971,994	3,483,691
Vested and Exercisable	$ 46,840,559

STOCKHOLDERS' EQUITY (Details 1) (Warrants, USD $)	12 Months Ended
STOCKHOLDERS' EQUITY (Details 1) (Warrants, USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Class of Warrant or Right [Line Items]
Weighted average fair value	$ 2.83	$ 2.05	$ 0.16
Term (in years)		5 years
Dividend yield	0.00%	0.00%	0.00%
Minimum
Class of Warrant or Right [Line Items]
Risk-free interest rate	0.88%	0.72%	0.91%
Volatility	44.29%	44.64%	39.13%
Term (in years)	5 years		5 years
Maximum
Class of Warrant or Right [Line Items]
Risk-free interest rate	1.12%	1.04%	3.48%
Volatility	45.89%	44.81%	51.83%
Term (in years)	6 years		10 years

STOCKHOLDERS' EQUITY (Details 2) (Stock Options)	12 Months Ended
STOCKHOLDERS' EQUITY (Details 2) (Stock Options)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.65%	0.61%	0.91%
Expected Volatility	33.35%	40.77%	37.92%
Expected term	5 years	5 years	5 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.71%	2.23%	2.54%
Expected Volatility	45.76%	46.01%	40.48%
Expected term	6 years 3 months	6 years 3 months	6 years 3 months

STOCKHOLDERS' EQUITY (Details 3) (USD $)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Number Options

Options outstanding, ending

Stock Options

Number Options

Options outstanding, beginning

13,733,488

10,590,161

Options Granted

2,583,677

5,121,250

10,682,218

^[1]

Options Exercised

(75,423)

(1,931,788)

(92,057)

Options Expired

(250)

Options Cancelled

(608,750)

(46,135)

Options outstanding, ending

15,632,742

13,733,488

10,590,161

Vested and exercisable

11,282,627

Weighted Average Exercise Price

Options outstanding, beginning

$ 1.16

$ 0.16

Granted

$ 3.31

$ 2.8

$ 0.16

^[1]

Exercised

$ 0.13

$ 0.19

Options outstanding, ending

$ 1.44

$ 1.16

$ 0.16

Vested and exercisable

$ 0.8

Weighted Average Remaining Contractual Life

Options outstanding, beginning

7 years 8 months 12 days

7 years 7 months 6 days

Granted

9 years 9 months 18 days

9 years 8 months 12 days

7 years 7 months 6 days

^[1]

Options outstanding, ending

7 years 2 months 12 days

7 years 8 months 12 days

7 years 7 months 6 days

Vested and exercisable

6 years 6 months

Aggregate Intrinsic Value

Options outstanding, beginning

$ 26,804,117

$ 14,067,649

Granted

$ 4,920,981

$ 1,737,530

$ 14,188,484

^[1]

Options outstanding, ending

58,878,132

26,804,117

14,067,649

Vested and exercisable

$ 48,321,930

[1]

This includes (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Options including the number of shares vested.

INCOME TAXES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred Income Tax Assets:
Net operating losses	$ 14,773,537	$ 5,920,861	$ 748,404
R&D Credit	547,511	186,346
Total deferred income tax asset	15,321,048	6,107,207	748,404
Valuation allowance	(15,321,048)	(6,107,207)	(748,404)
Deferred Income Tax Assets, net	$ 0	$ 0	$ 0

INCOME TAXES (Details 1)	12 Months Ended
INCOME TAXES (Details 1)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]
Federal statutory tax rate	35.00%	35.00%	35.00%
State tax rate, net of federal tax benefit	5.80%	5.50%	0.00%
Adjustment in valuation allowances	(32.40%)	(18.20%)	(5.80%)
Permanent and other differences	(8.40%)	(22.30%)	(29.20%)
Provision (Benefit) for Income Taxes	0.00%	0.00%	0.00%

RELATED PARTIES (Details Narrative) (USD $)	12 Months Ended			0 Months Ended	12 Months Ended										1 Months Ended					0 Months Ended						1 Months Ended	0 Months Ended
RELATED PARTIES (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 04, 2011 Agreement and Plan of Merger with VitaMed	Dec. 31, 2013 Brian Bernick	Dec. 31, 2012 Brian Bernick	Dec. 31, 2011 Brian Bernick	Dec. 31, 2013 Stock Purchase Agreement With Pernix Therapeutics LLC	Dec. 31, 2012 Stock Purchase Agreement With Pernix Therapeutics LLC	Dec. 31, 2011 Stock Purchase Agreement With Pernix Therapeutics LLC	Jun. 30, 2012 Non-affiliated third party	Nov. 13, 2012 Mr. Finizio	Nov. 13, 2012 Mr. Milligan	Nov. 13, 2012 Reich Family Limited LP	Jun. 30, 2012 VitaMed Promissory Notes	Oct. 30, 2011 VitaMed Promissory Notes	Jun. 30, 2011 VitaMed Promissory Notes	Nov. 13, 2012 VitaMed Promissory Notes	Mar. 31, 2011 VitaMed Promissory Notes	Oct. 04, 2012 VitaMed Promissory Notes Brian Bernick	Jun. 30, 2012 VitaMed Promissory Notes Brian Bernick	Mar. 31, 2011 VitaMed Promissory Notes Mr. Finizio	Mar. 31, 2011 VitaMed Promissory Notes Mr. Milligan	Mar. 31, 2011 VitaMed Promissory Notes Reich Family Limited LP	Dec. 31, 2011 Notes Issued to Mr. Finizio And Mr. Milligan	Jun. 30, 2012 Notes Issued to Mr. Finizio	Oct. 04, 2012 Notes Issued to Mr. Milligan
Related Party Transaction [Line Items]
Line of credit												$ 179,000	$ 179,000	$ 179,000				$ 299,220	$ 300,000			$ 100,000	$ 100,000	$ 100,000
Aggregate principal amount																	500,000								100,000
Aggregate remaining principal amount																					100,000
Repayments of notes payable	4,691,847	1,850,000	200,000													50,000	200,000			100,000
Acrued interest paid	212,853	17,253	696												2,160					5,341						888	1,519
Shares reserved for future isssuance				70,000,000
Description of lock in period				Each stockholder agreed that during a lock-up period from the date of the lock-up agreements until 18 months thereafter they would not make or cause any sale of our common stock. After the completion, each stockholder agreed not to sell or dispose of more than 2.5% of the stockholder's aggregate Common Stock or shares reserved for issuance under stock options and warrants per quarter over the following 12-month period, or the Dribble Out Period. Upon the completion of the Dribble Out Period, the Agreements will terminate.
Transaction amounts					0	2,632	20,669	0	404,000	19,000
Receivables outstanding					0	1,272	0	46,000	308,000	19,000
Legal fee reimbursement								$ 249,981	$ 0
Number of shares purchased											100,000						613,718

BUSINESS CONCENTRATIONS (Details Narrative)	12 Months Ended
BUSINESS CONCENTRATIONS (Details Narrative)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration Risk	98.00%	76.00%	95.00%
Revenue - Prescription dietary
Concentration Risk [Line Items]
Concentration Risk	79.00%	63.00%	42.00%
Net Revenue
Concentration Risk [Line Items]
Concentration Risk	64.00%	28.00%
Deferred revenue
Concentration Risk [Line Items]
Concentration Risk	97.00%	98.00%

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	6 Months Ended		12 Months Ended
	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]
Non-cancelable operating lease term			63 months
Monthly Base rent of leases			$ 30,149
Future minimum lease payments	1,766,252		1,766,252
Rental Expense	180,894	60,168		106,315	122,752
Rental Income	$ 32,963

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2013
Future minimum rental payments
2014	$ 316,039
2015	371,240
2016	382,377
2017	393,848
2018	302,748
Total minimum lease payments	1,766,252
Noncancelable sub-lease income	(38,956)
Net minimum lease payments	$ 1,727,296

SELECTED QUARTERLY FINANCIAL DATA (Details) (USD $)	3 Months Ended								12 Months Ended
SELECTED QUARTERLY FINANCIAL DATA (Details) (USD $)	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 2,863,000	$ 2,295,000	$ 2,081,000	$ 1,537,000	$ 1,241,000	$ 1,036,000	$ 819,000	$ 722,000	$ 8,775,598	$ 3,818,013	$ 2,088,177
Gross profit	2,396,000	1,646,000	1,617,000	1,157,000	908,000	729,000	447,000	386,000	6,816,001	2,469,900	1,141,065
Net loss	$ (8,361,000)	$ (7,673,000)	$ (6,009,000)	$ (6,376,000)	$ (5,727,000)	$ (4,253,000)	$ (11,850,000)	$ (13,290,000)	$ (28,419,313)	$ (35,120,235)	$ (12,913,365)
Loss per common share, basic and diluted (in dollars per shares)	$ (0.06)	$ (0.06)	$ (0.05)	$ (0.06)	$ (0.06)	$ (0.04)	$ (0.14)	$ (0.16)	$ (0.22)	$ (0.38)	$ (0.21)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

SUBSEQUENT EVENTS (Details Narrative) (Stock Options)

12 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 06, 2014

Subsequent Event

Options Granted

2,583,677

5,121,250

10,682,218

^[1]

390,000

Exercise period

10 years

Date awards vest

2014-12-31

[1]

FIXED ASSETS (Details Narrative) (USD $)	12 Months Ended
FIXED ASSETS (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Depreciation Expense	$ 47,883	$ 27,484	$ 25,686
Leasehold Improvements
Decrease accumulated depreciation	$ 11,980

OTHER CURRENT LIABILITIES (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Other Liabilities, Current [Abstract]
Dividends Payable, amount per share	$ 0.40
Unclaimed dividends	$ 41,359	$ 41,359

INCOME TAXES (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Federal
Net operating loss carryforwards	$ 37,000,000
State
Net operating loss carryforwards	$ 35,000,000	$ 35,000,000	$ 35,000,000